Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02992236
Recruitment Status : Completed
First Posted : December 14, 2016
Results First Posted : August 9, 2019
Last Update Posted : August 9, 2019
Winicker Norimed GmbH
Information provided by (Responsible Party):
Vasopharm GmbH

Brief Summary:
Analysis of the effect of the NO-Synthase inhibitor VAS203 (6 hours infusion of 10 mg/kg) on renal function and perfusion in 16 healthy subjects.

Condition or disease Intervention/treatment Phase
Renal Function Impairment in Healthy Volunteers Drug: VAS203 Drug: Saline Phase 1

Detailed Description:

Analysis of the effect of i.v. VAS203 on renal function and perfusion in healthy subjects.

Primary objective:

Possible adverse effect of VAS203 on the Renal Plasma Flow (RPF) and the Glomerular Filtration Rate (GFR) during and after 6 hours of constant-rate iv. infusion of 10 mg/kg VAS203.

Secondary objective:

To analyse the effects of VAS203 on

  • filtration fraction
  • hemodynamics (afferent and efferent resistance, intraglomerular pressure)
  • markers of kidney injury and renal function
  • systolic, mean and diastolic brachial blood pressure
  • Plasma Pharmacokinetic of VAS203 and its first metabolite.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers
Study Start Date : August 2015
Actual Primary Completion Date : May 2016
Actual Study Completion Date : November 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Tests

Arm Intervention/treatment
Placebo Comparator: Placebo
Infusion (6 hours) of Saline
Drug: Saline
Infusion of saline
Other Name: 0.9% sodium chloride

Active Comparator: VAS203
Infusion (6 hours) of VAS203 (10 mg/kg)
Drug: VAS203
Infusion of NO-Synthase inhibitor VAS203
Other Name: Ronopterin

Primary Outcome Measures :
  1. Renal Plasma Flow [ Time Frame: 0, 2h, 4h, 6h and 8 h after start of infusion ]
    Renal plasma flow measurement by para-Amino-Hippuric-Acid Clearance Method

  2. Glomerular Filtration Rate [ Time Frame: 0, 2h, 4h, 6h and 8 h after start of infusion ]
    by para-Amino-Hippuric Acid Clearance Method

Secondary Outcome Measures :
  1. Serum Creatinine Concentration [ Time Frame: 0, 2h, 4h, 6h, 8h, 10h, 24h and 48h after start of infusion ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Informed consent in writing available.
  2. Willing and able to comply with all requirements of the study.
  3. Male, 18 and 45 years (inclusive).
  4. Subject has a body weight between 60 kg and 100 kg, extremes included.
  5. BMI 18 to 27 kg/m2.
  6. Non-smoker
  7. Serum creatinine within reference range (≤1.2 mg/dL) and Cockroft-Gault Clearance > 90 ml/min
  8. Good general health as judged by the Investigator, as determined by medical history, physical examination, vital signs (systolic and diastolic blood pressure and pulse rate) and clinical laboratory parameters (clinical chemistry, hematology, and urinalysis)

Exclusion Criteria:

  1. Clinically significant abnormalities in physical examination, vital signs or clinical laboratory parameters (according to the Investigator's judgment).
  2. Serum glutamate oxaloacetate transaminase or glutamate-pyruvate transaminase > 2-times above the upper limit of normal range.
  3. Subject with Cockcroft-Gault clearance < 90 ml/min.
  4. Clinically significant history of cardiovascular disease or any known present cardiovascular disease.
  5. History of clinically significant neurological, gastrointestinal, renal, hepatic, psychological, pulmonary, metabolic, endocrine, hematological, or other major disorders.
  6. Office blood pressure at screening higher than 160/100 mmHg, or lower than 95/55 mmHg.
  7. Office heart rate at screening after at least 5 minutes outside the range of 50- 99 beats per minute (inclusive).
  8. Concomitant use of OTC medication within 1 week prior to dosing, except use of paracetamol (up to 2 g/day).
  9. Participation in any other clinical study within 30 days prior to inclusion in this -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02992236

Layout table for location information
Universitätsklinik Erlangen
Erlangen, Germany, 91054
Sponsors and Collaborators
Vasopharm GmbH
Winicker Norimed GmbH
Layout table for investigator information
Principal Investigator: Roland E Schmieder, Prof. Dr. Universitätsklinik Erlangen
Layout table for additonal information
Responsible Party: Vasopharm GmbH Identifier: NCT02992236    
Other Study ID Numbers: VAS203/I/3/05
First Posted: December 14, 2016    Key Record Dates
Results First Posted: August 9, 2019
Last Update Posted: August 9, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided